Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Chantel Mozal

Physician Assistant, Medical Glen Mills, PA Physician Assistant

NPI 1730542424 CMS profile 10489153

1102 Baltimore Pike Ste 202, Glen Mills, PA 19342

Open in the dashboard

General payments

$14,529

652 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chantel Mozal of Glen Mills, PA is reported in the CMS Open Payments database as having received $14,529 across 652 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,360 215
2024 General $3,444 158
2023 General $3,728 146
2022 General $2,093 84
2021 General $904 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chantel Mozal
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Chantel Mozal were reported at $4,360. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Chantel Mozal Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $904 $156 $41–$563 $132
2022 $2,093 $185 $55–$649 $149
2023 $3,728 $199 $58–$717 $160
2024 $3,444 $206 $62–$740 $164
2025 $4,360 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $2,064 110 payments
  2. AbbVie, Inc. $1,802 100 payments
  3. Sun Pharmaceutical Industries Inc. $1,392 78 payments
  4. Lilly USA, LLC $1,302 37 payments
  5. Galderma Laboratories, L.P. $957 51 payments
  6. E.R. Squibb & Sons, L.L.C. $844 49 payments
  7. Incyte Corporation $742 20 payments
  8. Dermavant Sciences, Inc. $668 15 payments
  9. Regeneron Healthcare Solutions, Inc. $665 20 payments
  10. Novartis Pharmaceuticals Corporation $523 16 payments
  11. Other $3,569 156 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,641 639 payments
  2. Education $887 13 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $2,107 98 payments
  2. SOTYKTU $837 48 payments
  3. VTAMA $798 17 payments
  4. RINVOQ $793 47 payments
  5. OPZELURA $742 20 payments
  6. TALTZ $636 23 payments
  7. ILUMYA $627 48 payments
  8. EBGLYSS $576 14 payments
  9. SKYRIZI $570 28 payments
  10. DUPIXENT $553 17 payments
  11. Other $8,255 434 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

427

Median for Physician Assistant: 241

Drug cost

$73,829

Median for Physician Assistant: $4,110

Branded share of claims

10.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 16 $63,891
Clobetasol Propionate Generic 58 $2,142
Metronidazole Generic 30 $1,820
Fluorouracil Generic 24 $1,805
Doxycycline Hyclate Generic 31 $968
Ketoconazole Generic 47 $716
Triamcinolone Acetonide Generic 50 $612
Betamethasone Dipropionate Generic 13 $542
Minoxidil Generic 26 $311
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 17 $263

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$423,129

Of which drugs: $312,627

Medicare patients

804

Average age 74

Services billed

5,574

510 women, 294 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 45%
Ischemic heart disease 22%
Osteoporosis 22%
Diabetes 18%
Cancer 17%
Depression 16%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, tildrakizumab, 1 mg J3245 Office 11 2,900 $308,057
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 11 15 $4,556
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 19 $13

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $349
$349 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $342
$342 — —
DUPIXENT
  • GENZYME CORPORATION $133
  • SANOFI-AVENTIS U.S. LLC $85
  • Regeneron Healthcare Solutions, Inc. $56
$274 16 —
VTAMA
  • Dermavant Sciences, Inc. $250
$250 — —
RINVOQ
  • AbbVie, Inc. $238
$238 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

652 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record